Ouro Medicines Launches with $120 Million Series A Funding to Develop Immune Reset Therapies
Ouro Medicines, a San Francisco-based biotechnology company, has launched with $120 million in Series A funding to pioneer immune reset therapies for chronic immune-mediated diseases. The company’s innovative approach aims to provide long-term relief for patients by selectively targeting and modulating the immune system.
The Series A financing round was co-led by TPG Life Sciences Innovations, NEA, and Norwest Venture Partners, with additional participation from Monograph Capital, GSK, UPMC Enterprises, Boyu/Zoo Capital, and LongRiver Investments. This strong backing from leading investors underscores the potential of Ouro Medicines’ technology in addressing the growing burden of autoimmune and inflammatory diseases.
Ouro Medicines’ lead product candidate, OM336, is a BCMA-directed bispecific T cell engager licensed from Keymed Biosciences. Designed to selectively target B cells, OM336 aims to reset the immune system, offering a novel therapeutic approach for diseases such as lupus, rheumatoid arthritis, and multiple sclerosis.
The newly acquired funding will support the advancement of OM336 through clinical development, with initial trials expected to begin later this year. Ouro Medicines also plans to expand its pipeline with additional discovery programs focused on B cell biology, aiming to develop a broad portfolio of immune-modulating therapies.
Founded by Monograph Capital in collaboration with GSK, Ouro Medicines brings together a team of experienced scientists, drug developers, and industry leaders. CEO Dr. Jane Huang, formerly of BeiGene, expressed excitement about the company’s mission to redefine treatment paradigms for immune-mediated diseases through precise immune modulation.
The investment from GSK, a global pharmaceutical leader, highlights the strategic importance of immune reset therapies in the future of healthcare. GSK’s involvement is expected to provide valuable insights and resources as Ouro Medicines advances its clinical programs and explores new therapeutic opportunities.
Ouro Medicines is poised to become a key player in the field of immunology, leveraging cutting-edge science to develop therapies that offer durable benefits for patients with chronic immune conditions. With strong financial support and a promising pipeline, the company is well-positioned to make significant contributions to the treatment of immune-mediated diseases.
